<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36510683</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1988-9518</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</Title><ISOAbbreviation>Rev Esp Quimioter</ISOAbbreviation></Journal><ArticleTitle>Insights for COVID-19 in 2023.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>124</EndPage><MedlinePgn>114-124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.37201/req/122.2022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">martin13dec2022</ELocationID><Abstract><AbstractText>Predictions for a near end of the pandemic by the World Health Organization should be interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of classical mRNA vaccines (BT162b2 or mRNA-1273) is low and short-lived in preventing SARS-CoV-2 infection in its predominant variant (Omicron). However, its efficacy is high against severe symptomatic infection, hospitalization and death. The new vaccines being introduced are bivalent and active against the Omicron variants. Potential new vaccines to be introduced in the coming year include a vaccine based on a recombinant protein that emulates the receptor binding domain of the Spike protein under development by the Spanish company Hipra, as well as vaccines for nasal or oral administration. Available information suggests that vaccines against COVID-19 can be administered in association with influenza vaccination without particular complications. New drugs against COVID-19, both antiviral and anti-inflammatory, are under investigation, but this does not seem to be the case with monoclonal antibodies. The indication to use masks in some circumstances will be maintained next year in view of the accumulation of scientific data on their efficacy. Finally, the long COVID or Post-COVID syndrome may continue to affect a very high proportion of patients who have had the disease, requiring combined diagnostic and therapeutic resources.</AbstractText><CopyrightInformation>&#xa9;The Author 2022. Published by Sociedad Espa&#xf1;ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;n S&#xe1;nchez</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Sell&#xe9;s</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Molero Garc&#xed;a</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Moreno Guill&#xe9;n</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Artalejo</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Ruiz-Galiana</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cant&#xf3;n</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>De Lucas Ramos</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Botella</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Lled&#xf3;</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Sampelayo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Pav&#xf3;n</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Del Castillo</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Delgado</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Bouza</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a Cl&#xed;nica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain. emilio.bouza@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Quimioter</MedlineTA><NlmUniqueID>9108821</NlmUniqueID><ISSNLinking>0214-3429</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las predicciones para un pr&#xf3;ximo fin de la pandemia de la Organizaci&#xf3;n Mundial de la Salud deben interpretarse con precauci&#xf3;n. La evidencia actual indica que la eficacia de una cuarta dosis de las vacunas cl&#xe1;sicas ARNm (BNT162b2 o mRNA-1273) es baja y de corta duraci&#xf3;n para prevenir la infecci&#xf3;n de SARS-CoV-2 en su variante predominante (Omicron). No obstante, su eficacia es alta frente a la infecci&#xf3;n sintom&#xe1;tica grave, hospitalizaci&#xf3;n y muerte. Las nuevas vacunas que est&#xe1;n siendo introducidas son bivalentes y activas frente a las variantes Omicron. Entre las potenciales nuevas vacunas que se introducir&#xe1;n en el pr&#xf3;ximo a&#xf1;o, se encuentra una vacuna basada en una prote&#xed;na recombinante que emula el dominio de uni&#xf3;n al receptor de la prote&#xed;na Spike en desarrollo por la compa&#xf1;&#xed;a espa&#xf1;ola Hipra, as&#xed; como vacunas de administraci&#xf3;n nasal u oral. La informaci&#xf3;n disponible apunta a que las vacunas frente al COVID-19 podr&#xe1;n administrarse asociadas a la vacunaci&#xf3;n antigripal sin particulares complicaciones. Se encuentran en investigaci&#xf3;n nuevos f&#xe1;rmacos frente a COVID-19 tanto antivirales como anti-inflamatorios pero no parece ocurrir lo mismo con los anticuerpos monoclonales. La indicaci&#xf3;n de utilizar mascarillas en algunas circunstancias se mantendr&#xe1; el pr&#xf3;ximo a&#xf1;o en vista a la acumulaci&#xf3;n de datos cient&#xed;ficos sobre su eficacia. Finalmente, el s&#xed;ndrome del COVID largo o Post-COVID puede que siga afectando a una proporci&#xf3;n muy elevada de los pacientes que sufrieron la enfermedad, requiriendo recursos diagn&#xf3;sticos y terap&#xe9;uticos combinados.</AbstractText><CopyrightInformation>&#xa9;The Author 2022. Published by Sociedad Espa&#xf1;ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long-term COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">bivalent vaccines</Keyword><Keyword MajorTopicYN="N">investigational drugs</Keyword><Keyword MajorTopicYN="N">nasal and oral vaccines</Keyword><Keyword MajorTopicYN="N">use of masks</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>2</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36510683</ArticleId><ArticleId IdType="pmc">PMC10066911</ArticleId><ArticleId IdType="doi">10.37201/req/122.2022</ArticleId><ArticleId IdType="pii">martin13dec2022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O.M.S . Press Conference. Tedros Ghebreyesus. 22-09-22. 2022.</Citation></Reference><Reference><Citation>Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022. Jul;94(7):2969-2976. doi: 10.1002/jmv.27697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27697</ArticleId><ArticleId IdType="pmc">PMC9088621</ArticleId><ArticleId IdType="pubmed">35246846</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;lper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton LS, Geurts B, et al. . Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 2022;13:940562. DOI: 10.3389/fimmu.2022.940562</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.940562</ArticleId><ArticleId IdType="pmc">PMC9449804</ArticleId><ArticleId IdType="pubmed">36091023</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TTB, Vasanthakumaran T, Thi Hien HN, Hung IC, Luu MN, Khan ZA, et al. . SARS-CoV-2 Omicron and its current known unknowns: A narrative review. Rev Med Virol. 2022:e2398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538895</ArticleId><ArticleId IdType="pubmed">36150052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. . Omicron variant showed lower neutralizing sensitivity than other SARSCoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11(1):337-43. :337-343. doi: 10.1080/22221751.2021.2022440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2022440</ArticleId><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder T, Koch J, Vygen-Bonnet S, K&#xfc;lper-Schiek W, Pilic A, Reda S, et al. . Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review., 1 January to 14 May 2021. Euro. Surveill. 2021. Jul 26(28):2100563. doi: 10.2807/1560-7917.ES.2021.26.28.2100563.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.28.2100563</ArticleId><ArticleId IdType="pmc">PMC8284046</ArticleId><ArticleId IdType="pubmed">34269175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad . Actualizaci&#xf3;n de la situaci&#xf3;n epidemiol&#xf3;gica de las variantes de SARS-CoV-2 en Espa&#xf1;a. 26 de septiembre de 2022. Available at: https://wwwsanidadgobes/profesionales/salud-Publica/ccayes/alertasActual/nCov/documentos/COVID19_Actual-izacion_variantes_20220926pdf.</Citation></Reference><Reference><Citation>Khan NA, Al-Thani H, El-Menyar A. The emergence of new SARSCoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Med Infect Dis. 2022;45:102246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8687713</ArticleId><ArticleId IdType="pubmed">34942376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. . Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386(18):1712-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006780</ArticleId><ArticleId IdType="pubmed">35381126</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hern&#xe1;n MA, et al. . Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2022;386(17):1603-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020581</ArticleId><ArticleId IdType="pubmed">35417631</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Sergienko R, Friger M, Peretz A, Beckenstein T, Yaron S, et al. . Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med. 2022;28(7):1486-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">35468276</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, et al. . Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. Bmj. 2022;378:e071502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257064</ArticleId><ArticleId IdType="pubmed">35793826</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Baggs J, Marquez P, Abara WE, Baumblatt J, Blanc PG, et al. . Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged &#x2265;50 Years-United States, March 29, 2022-July 10, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(30):971-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345177</ArticleId><ArticleId IdType="pubmed">35900925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Baggs J, Marquez P, Abara WE, Olubajo B, Myers TR, et al. . Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(9):347-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893335</ArticleId><ArticleId IdType="pubmed">35239637</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. Jama. 2021;325(13):1318-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33635317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions. Microbiol Res. 2022;265:127204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482093</ArticleId><ArticleId IdType="pubmed">36152612</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH. Covid-19 Vaccines-Immunity, Variants, Boosters. N Engl J Med. 2022;387(11):1011-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. . Duration of effectiveness of vaccines against SARSCoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA . First adapted COVID-19 booster vaccines recommended for approval in the EU. 01/09/2022. Available at: https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu.</Citation></Reference><Reference><Citation>EMA . Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval. 12/09/2022. (Accessed, october, 2022). Available at: https://www.ema.europa.eu/en/news/adapted-vaccine-targeting-ba4-ba5-omicron-vari-ants-original-sars-cov-2-recommended-approval</Citation></Reference><Reference><Citation>FDA . Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. (Accessed on Jan 10th , 2022). 2022.  . Available at: https://www.fda.gov/media/137566/download</Citation></Reference><Reference><Citation>Telenti A, Hodcroft EB, Robertson DL. The Evolution and Biology of SARS-CoV-2 Variants. Cold Spring Harb Perspect Med. 2022;12(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159258</ArticleId><ArticleId IdType="pubmed">35444005</ArticleId></ArticleIdList></Reference><Reference><Citation>Consejo Interterritorial de Salud . Ponencia de Programa y Regis-tro de Vacunaciones. Recomendaciones de vacunaci&#xf3;n frente a COVID-19 para el oto&#xf1;o en Espa&#xf1;a. 22
septiembre
2022. (accessed october, 2022). Available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Recomendaciones_vacunacion_Otono_Covid_VF.pdf</Citation></Reference><Reference><Citation>Corominas J, Garriga C, Prenafeta A, Moros A, Ca&#xf1;ete M, Barreiro A, et al. . Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. medRxiv 2022070522277210; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10102678</ArticleId><ArticleId IdType="pubmed">37131861</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreiro A, Prenafeta A, Bech-Sabat G, et al. . Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2. bioRxiv 2021: 202111224691172022.</Citation></Reference><Reference><Citation>Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, et al. . Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940714</ArticleId><ArticleId IdType="pubmed">35051989</ArticleId></ArticleIdList></Reference><Reference><Citation>Waltz E. How nasal-spray vaccines could change the pandemic. Nature. 2022;609(7926):240-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">36068305</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Su J, Ma Y, Zhang W, Tang S. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Front Immunol. 2022;13:945930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9459021</ArticleId><ArticleId IdType="pubmed">36090988</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Maggi F, Casadevall A. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. Viruses. 2022;14(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8878800</ArticleId><ArticleId IdType="pubmed">35215783</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, et al. . COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022:1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935456</ArticleId><ArticleId IdType="pubmed">35258416</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell MW, Mestecky J. Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission. Front Immunol. 2022;13:957107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9428579</ArticleId><ArticleId IdType="pubmed">36059541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwell BL, Melo MB, Xiao P, Lemnios AA, Li N, Chang JYH, et al. . Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci Transl Med. 2022;14(654):eabn1413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9835395</ArticleId><ArticleId IdType="pubmed">35857825</ArticleId></ArticleIdList></Reference><Reference><Citation>Heida R, Hinrichs WL, Frijlink HW. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Rev Vaccines. 2022;21(7):957-74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33749491</ArticleId></ArticleIdList></Reference><Reference><Citation>Waltz E. China and India approve nasal COVID vaccines-are they a game changer? Nature. 2022;609(7927):450.</Citation><ArticleIdList><ArticleId IdType="pubmed">36071228</ArticleId></ArticleIdList></Reference><Reference><Citation>Adashi EY, Gruppuso PA. Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable. Am J Prev Med. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9271463</ArticleId><ArticleId IdType="pubmed">35906142</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L, Tang R, Wu S, Guo X, Hou L, Chen X, et al. . Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously. medRxiv 2022072622278072; . 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10519268</ArticleId><ArticleId IdType="pubmed">36503413</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbein H, K&#xfc;mmel LS, Fragkou PC, Th&#xf6;lken C, H&#xfc;nerbein BL, Reiter R, et al. . Respiratory viral co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-analysis. Rev Med Virol. 2022:e2365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347814</ArticleId><ArticleId IdType="pubmed">35686619</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W, Wang H, Sun C, Li N, Guo X, Song Q, et al. . The Association Between Previous Influenza Vaccination and COVID-19 Infection Risk and Severity: A Systematic Review and Meta-analysis. Am J Prev Med. 2022;63(1):121-30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920881</ArticleId><ArticleId IdType="pubmed">35410774</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Riccio M, Lorini C, Bonaccorsi G, Paget J, Caini S. The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature. Int J Environ Res Public Health. 2020;17(21).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672609</ArticleId><ArticleId IdType="pubmed">33121070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Deng W, Qi F, Lv Q, Song Z, Liu J, et al. . Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduct Target Ther. 2021;6(1):200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8134832</ArticleId><ArticleId IdType="pubmed">34016949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, et al. . Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585490</ArticleId><ArticleId IdType="pubmed">34774197</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenyu W, Xiaoqian D, Bo C, Xuan D, Zeng W, Hangjie Z, et al. . Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine. 2022;40(36):5356-65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9343811</ArticleId><ArticleId IdType="pubmed">35933275</ArticleId></ArticleIdList></Reference><Reference><Citation>Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, et al. . Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged &#x2265;65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022;10(4):392-402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803382</ArticleId><ArticleId IdType="pubmed">35114141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling RR, Ramanathan K, Tan FL, Tai BC, Somani J, Fisher D, et al. . Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022;10(7):679-88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9000914</ArticleId><ArticleId IdType="pubmed">35421376</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakova-Sivak I, Stepanova E, Matyushenko V, Niskanen S, Mezhenskaya D, Bazhenova E, et al. . Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector. Vaccines (Basel). 2022;10(7).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9318028</ArticleId><ArticleId IdType="pubmed">35891306</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao K, Wang X, Peng H, Ding L, Wang X, Hu Y, et al. . A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. J Virol. 2022;96(4):e0157821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865568</ArticleId><ArticleId IdType="pubmed">34908443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, Wu M, Zhou C, Lu X, Huang B, Zhang N, et al. . Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines. 2022;7(1):84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9315335</ArticleId><ArticleId IdType="pubmed">35882870</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Li J, Sun C, Chi H, Luo D, Wang R, et al. . Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae. Adv Mater. 2022;34(21):e2200443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073961</ArticleId><ArticleId IdType="pubmed">35332581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsley WG, Blachere FM, Law BF, Beezhold DH, Noti JD. Efficacy of face masks, neck gaiters and face shields for reducing the expulsion of simulated cough-generated aerosols. Aerosol Sci Technol. 2021;55(4):449-57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345365</ArticleId><ArticleId IdType="pubmed">35924077</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer EP, Fischer MC, Grass D, Henrion I, Warren WS, Westman E. Low-cost measurement of face mask efficacy for filtering expelled droplets during speech. Sci Adv. 2020;6(36).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467698</ArticleId><ArticleId IdType="pubmed">32917603</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Dhanak M, Frankenfield J. Visualizing the effectiveness of face masks in obstructing respiratory jets. Phys Fluids (1994). 2020;32(6):61708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327717</ArticleId><ArticleId IdType="pubmed">32624649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl P, Bhattacharjee S, de Silva C, Chughtai AA, Doolan C, Mac-Intyre CR. Face coverings and mask to minimise droplet dispersion and aerosolisation: a video case study. Thorax. 2020;75(11):1024-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">32709611</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. . Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020;11(11):Cd006207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094623</ArticleId><ArticleId IdType="pubmed">33215698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou R, Dana T, Jungbauer R, Weeks C, McDonagh MS. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings : A Living Rapid Review. Ann Intern Med. 2020;173(7):542-55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322812</ArticleId><ArticleId IdType="pubmed">32579379</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liang M, Gao L, Ayaz Ahmed M, Uy JP, Cheng C, et al. . Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. Am J Infect Control. 2021;49(7):900-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748970</ArticleId><ArticleId IdType="pubmed">33347937</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen HM, et al. . An evidence review of face masks against COVID-19. Proc Natl Acad Sci U S A. 2021;118(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848583</ArticleId><ArticleId IdType="pubmed">33431650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabatabaeizadeh SA. Airborne transmission of COVID-19 and the role of face mask to prevent it: a systematic review and meta-analysis. Eur J Med Res. 2021;26(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7776300</ArticleId><ArticleId IdType="pubmed">33388089</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateos Maz&#xf3;n M, Mart&#xed;nez Caballero CM, Mateos Maz&#xf3;n JJ, de Carlos Negro L, Del Otero Sanz L. [Observational study of the adherence to the correct use of face masks by the general population in open public places during two periods of the COVID-19 pandemic in four Spanish cities.]. Rev Esp Salud Publica. 2022;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">35095094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wismans A, van der Zwan P, Wennberg K, Franken I, Mukerjee J, Baptista R, et al. . Face mask use during the COVID-19 pandemic: how risk perception, experience with COVID-19, and attitude towards government interact with country-wide policy stringency. BMC Public Health. 2022;22(1):1622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412789</ArticleId><ArticleId IdType="pubmed">36028876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, von Buchwald C, Todsen T, Norsk JB, et al. . Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial. Ann Intern Med. 2021;174(3):335-43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707213</ArticleId><ArticleId IdType="pubmed">33205991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuehn BM. Bus and Urban Transit Workers Have Highest COVID-19 Risk. Jama. 2022;328(12):1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">36166006</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA news release . Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 months of age. 2022.. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children.</Citation></Reference><Reference><Citation>Centers for Disease Control, Practices. ACoI. COVID-19 ACIP Vaccine Recommendations
2022. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html.</Citation></Reference><Reference><Citation>Wanga V, Gerdes ME, Shi DS, Choudhary R, Dulski TM, Hsu S, et al. . Characteristics and Clinical Outcomes of Children and Adolescents Aged &lt;18 Years Hospitalized with COVID-19-Six Hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1766-72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8736272</ArticleId><ArticleId IdType="pubmed">34968374</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. . Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386(1):35-46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F, et al. . Effectiveness of BNT162b2 vaccine against SARSCoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Lancet. 2022;400(10346):97-103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant. Jama. 2022;327(22):2242-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107062</ArticleId><ArticleId IdType="pubmed">35559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. . Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JR. Centers for Disease Control and Prevention. Advisory Committee on immunization practices COVID- 19 vaccine safety update 2022. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-01-05/06_COVID_Oliver_2022-01-05.pdf.</Citation></Reference><Reference><Citation>Ministerio de Sanidad . Gobierno de Espa&#xf1;a. Estrategia de Vacunaci&#xf3;n COVID-19. 2022. Available at: https://www.vacunacovid.gob.es/.</Citation></Reference><Reference><Citation>Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. . Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. J Med Chem. 2022;65(9):6499-512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. . Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607(7917):119-27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579982</ArticleId><ArticleId IdType="pubmed">35576972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, et al. . A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. Antimicrob Agents Chemother. 2022:e0069722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578433</ArticleId><ArticleId IdType="pubmed">36098519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyndall JDA. S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2. J Med Chem. 2022;65(9):6496-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35507419</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenberger S, Hurdiss DL, Walser M, Malvezzi F, Mayor J, Ryter S, et al. . The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. Nat Biotechnol. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9750863</ArticleId><ArticleId IdType="pubmed">35864170</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, et al. . Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial. Ann Intern Med. 2022;175(9):1266-74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384272</ArticleId><ArticleId IdType="pubmed">35939810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro R, Pinto E, Fernandes C, Sousa E. Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies. Mar Drugs. 2022;20(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230156</ArticleId><ArticleId IdType="pubmed">35736200</ArticleId></ArticleIdList></Reference><Reference><Citation>Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, et al. . Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance. 2022;5(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761492</ArticleId><ArticleId IdType="pubmed">35012962</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, et al. . A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent. Clin Cancer Res. 2022;28(13):2789-95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9774054</ArticleId><ArticleId IdType="pubmed">35416959</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnette KG, Gordon MS, Rodriguez D, et al. . Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. N Engl J Med 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">38319812</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Post_COVID-19_condition/Clinical_case_definition/2021.1. 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Bouza E, Cant&#xf3;n Moreno R, De Lucas Ramos P, Garc&#xed;a-Botella A, Garc&#xed;a-Lled&#xf3; A, G&#xf3;mez-Pav&#xf3;n J, et al. . [Post-COVID syndrome: A reflection and opinion paper]. Rev Esp Quimioter. 2021;34(4):269-279. doi: 10.37201/req/023.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.37201/req/023.2021</ArticleId><ArticleId IdType="pmc">PMC8329562</ArticleId><ArticleId IdType="pubmed">33878844</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Nicholson TR, Needham DM, Seylanova N, Parr C, Chen J, et al. . Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Med. 2022;20(1):50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813480</ArticleId><ArticleId IdType="pubmed">35114994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Naf-ilyan V, Zaccardi F, et al. . Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. Bmj. 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, Santoro MG, Schiaffino S, Remuzzi G, et al. . Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022:1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka S, Tsuzuki S, Suzuki M, Terada M, Akashi M, Osanai Y, et al. . Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J Infect Chemother. 2022;28(11):1546-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="pubmed">35963600</ArticleId></ArticleIdList></Reference><Reference><Citation>DM C. The Costs of Long COVID. JAMA Health Forum 2022;3(5):e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Sampalo A, Bernal-L&#xf3;pez MR, G&#xf3;mez-Huelgas R. Persistent COVID-19 syndrome. A narrative review. Rev Clin Esp (Barc). 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882405</ArticleId><ArticleId IdType="pubmed">35260380</ArticleId></ArticleIdList></Reference><Reference><Citation>Verduzco-Gutierrez M, Estores IM, Graf MJP, Barshikar S, Cabrera JA, Chang LE, et al. . Models of Care for Postacute COVID-19 Clinics: Experiences and a Practical Framework for Outpatient Physiatry Settings. Am J Phys Med Rehabil. 2021;100(12):1133-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8594397</ArticleId><ArticleId IdType="pubmed">34793373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf S, Zechmeister-Koss I, Erd&#xf6;s J. Possible long COVID healthcare pathways: a scoping review. BMC Health Serv Res. 2022;22(1):1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396575</ArticleId><ArticleId IdType="pubmed">35999605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>